A Randomised Phase IIb Trial of BEvACizumab Added to Temozolomide + IrinOtecan for Children with Refractory/Relapsed Neuroblastoma - BEACON Trial

Project Details

Short titleA Randomised Phase IIb Trial of BEvACizumab Added to Temozolomide + IrinOtecan for Children with Refractory/Relapsed Neuroblastoma - BEACON Trial
StatusActive
Effective start/end date1/01/13 → 30/11/24

Funding

  • SOLVING KIDS' CANCER
  • INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER (ITCC)
  • EUSA Pharma (UK) Limited
  • Cancer Research Uk